This perspective paper from an FDA-convened expert panel reports on regulatory and safety considerations for infant formula in the United States, arising from Operation Stork Speed, a joint FDA and Department of Health and Human Services initiative launched in March 2025 following the 2022 formula shortage. The panel addressed regulatory processes for new formulas, the GRAS pathway, and formula safety concerns including heavy metals. It contains no primary concentration measurements.
Key numbers
No primary formula concentration data are reported. The paper documents a critical regulatory gap: unlike the European Union, Canada, and Australia, the United States lacks enforceable maximum limits for heavy metals (lead, cadmium, arsenic, mercury) in infant formula.
| Finding | Detail |
|---|---|
| US heavy metal limits for formula | None enforceable; voluntary guidance only |
| EU, Canada, Australia comparison | These jurisdictions have enforceable limits for heavy metals in infant formula |
| FDA regulatory basis | Infant Formula Act of 1980; FDA guidance proposed 1996 |
| Contaminants mentioned as concerning | Heavy metals, PFAS, aflatoxins |
Methods (brief)
Expert panel perspective article based on a June 2025 FDA meeting transcript (publicly available). Not a primary research study. The panel reviewed regulatory processes and existing evidence. Authors include pediatric nutrition specialists, pharmacological scientists, and neonatologists.
Evidence fitness
This source supports US regulatory context documentation for infant formula stage 1. It establishes that the US has no enforceable heavy metal limits for infant formula as of mid-2025, in contrast with the EU, Canada, and Australia. This regulatory gap is relevant to understanding why US-based occurrence surveys may not reflect regulatory compliance monitoring.
The source does not supply concentration data and cannot contribute to literature-evidence rows.
Limitations
Perspective article, not a primary research study. Authors declare conflicts of interest (formula company consulting relationships are disclosed in the paper). The paper reflects a point-in-time regulatory snapshot (mid-2025 US context) and does not represent primary occurrence evidence.
Related evidence
- Infant Formula, Powder (Non-Soy)
- Infant Formula Stage 1
- sources/oconnor2026-us-infant-exposure-bioavailability-systematic-review
- Assessment of arsenic, cadmium, lead, mercury, and per- and polyfluoroalkyl substances concentrations in human milk and infant formula in the United States: a systematic review
Update history
No substantive edit history is available in this build. The full commit record is available in git.